Search results: (10000)
News ASH 2020: Two Real-World Perspectives on Experiences with Emicizumab Prophylaxis
Data presented at the ASH 2020 congress bring interesting insights regarding the administration of emicizumab in real clinical practice. It provides comprehensive information on the relatively high number of individuals treated with emicizumab in relation to persistence on treatment and adherence to it. Data from the EUHASS registry confirms the good safety profile of this treatment even in regular clinical practice across Europe.
News Efficacy of Baricitinib in Long-term Therapy of Rheumatoid Arthritis
Baricitinib selectively and reversibly inhibits Janus kinases JAK1 and JAK2 and is used in the treatment of adults with active rheumatoid arthritis (RA). Its safety during long-term administration has already been demonstrated by previous analyses, with treatment durations of up to 7 years. Equally important is the long-term efficacy of this drug, which was the focus of work presented in June of this year at the annual European rheumatology congress EULAR 2020.
News ESC 2022: What Do the Latest Real-World Data Say About the Use of DOACs in Atrial Fibrillation?
Why are real-world data so important? What new insights can they provide about established medications, such as direct oral anticoagulants (DOACs), in the treatment of patients with atrial fibrillation (AF)? What makes the GLORIA-AF registry unique, and what insights have been published from it this year? These topics were also discussed at the ESC 2022 Congress.
News Impact of Adequate Protein Intake on Morbidity and Mortality in Critically Ill Patients
The following text provides a summary of findings from clinical studies in the field of nutritional therapy for critically ill patients and its impact on protein metabolism and patient outcomes.
News European Registry of Patients with Alpha-1 Antitrypsin Deficiency EARCO Enrolls Patients
Insufficient identification of patients with alpha-1 antitrypsin deficiency (AATD) and a lack of knowledge about this disease have led to the launch of the European Registry EARCO, which is currently enrolling patients. The aim is to better describe the pathophysiology of the disease and the prognosis of these patients, and to create a validated prognostic tool to aid clinical decision-making.
News Safety and efficacy of dabigatran and other NOACs compared with warfarin in patients with atrial fibrillation – results of a large long-term prospective study
Anticoagulant therapy is key in the prevention of strokes in patients with atrial fibrillation. Until the introduction of new oral anticoagulants (NOACs), warfarin was the first-choice drug for these patients, but unlike NOACs, it requires careful dose titration and effect monitoring. The safety and benefits of using various anticoagulants were examined in the study below.
News Turoctocog Alfa Pegol with Extended Half-Life in the Treatment of Severe Hemophilia A
GlycoPEGylated recombinant factor VIII (rFVIII) with an extended half-life, turoctocog alfa pegol, has demonstrated prophylactic efficacy in patients with severe hemophilia A aged over 12. This product is administered only once every 4 days. In addition to a comparable reduction in the annual bleed rate to standard FVIII prophylaxis products, it has also shown sufficient efficacy in bleeding treatment and a minimal risk of inhibitory antibody formation.
News Intravenous Fixed Combination NEPA in the Prevention of Chemotherapy-Induced Vomiting
Summary data from several studies were used by the authors of the following analysis to evaluate the efficacy of the intravenous and oral forms of the fixed combination NEPA (netupitant/fosnetupitant + palonosetron) administered with dexamethasone in preventing chemotherapy-induced vomiting based on cisplatin or anthracycline and cyclophosphamide (AC).
News Safety and Efficacy of Long-term Tofacitinib Therapy in Patients with Active Psoriatic Arthritis – Interim Results of the OPAL Balance Study
Tofacitinib is a potent selective inhibitor of the Janus kinase (JAK) family indicated for the treatment of active psoriatic arthritis in adult patients. The efficacy and safety of tofacitinib in this population have been verified for 6 and 12 months through clinical studies OPAL. A study published in 2020 presents interim results of the extended phase of these studies, evaluating its efficacy and safety in the long term.
News Heart Failure in the Light of New ESC Guidelines
Dear Doctor, The Czech Society of Internal Medicine of ČLS JEP invites you to watch the symposium, which will take place on Wednesday, November 3rd, at 5 PM.
You can find more information in the invitation attached below.
You can find more information in the invitation attached below.
News Boy with Hemophilia A with Inhibitor − Case Study with Voting
Presented by: Assoc. Prof. MUDr. Jan Blatný, Ph.D., Department of Pediatric Hematology, University Hospital Brno
News Improvement of Executive Functions in Therapy of Dravet Syndrome with Fenfluramine in Preschool Children
Dravet syndrome is a rare genetic progressive epileptic encephalopathy that is usually accompanied by intellectual and behavioral disorders. Many children with this syndrome also struggle with deficits in executive functions. An analysis recently published in the journal Epilepsy & Behavior assessed the impact of fenfluramine therapy on executive functions in preschool children with this condition.
News Immunotolerance is still the goal of management of hemophilia A with inhibitor in the era of non-factor therapy
New molecules in hemophilia therapy have raised many questions, including regarding the significance and need for immune tolerance induction (ITI). Interesting conclusions from the FIT (Future of Immunotolerance Treatment) expert panel discussion on the future of ITI, its form, and indication were published in July 2019.
News Population Pharmacokinetics of Perioperative Administration of Coagulation Factors in Patients with von Willebrand Disease
For many patients with von Willebrand disease, the administration of coagulation factors is an important part of perioperative care. Due to the absence of pharmacokinetic models, predicting therapeutic levels is challenging, leading to a higher risk of bleeding or thrombotic events. To create the missing model, a long-term study was conducted by Dutch authors.
News Can the Treatment of Hypertension Prevent Recurrence of Atrial Fibrillation?
Atrial fibrillation (Afib) is the most common serious heart rhythm disorder and is responsible for a significant portion of deaths in the population. Hypertension is the most common and potentially modifiable risk factor for Afib. A newly published meta-analysis compares the effect of angiotensin receptor antagonism and calcium channel blockade on Afib recurrence in patients with hypertension and Afib.
News Tool for Predicting Cardiometabolic Risk in Young Patients with Psychotic Disorder
A study describing the development and validation of an algorithm for predicting cardiometabolic risk in patients with psychotic disorder, PsyMetRiC (Psychosis Metabolic Risk Calculator), was recently published in Lancet Psychiatry. British scientists have created a tool to estimate the risk of developing metabolic syndrome over the next 6 years, serving as a predictor of cardiovascular morbidity and mortality in young people with psychosis aged 16–35 years.
News COVID-19 and MS: Do You Know the Risk Factors? What the American Registry Analysis Showed
An article published in the March issue of the prestigious journal JAMA Neurology summarizes the findings of an analysis of the course of COVID-19 in patients with multiple sclerosis in North America. Which patients are at greater risk of severe infection?
News Benefit of Adding Erdosteine to Maintenance Treatment of COPD
Erdosteine is a mucoactive drug with anti-inflammatory, antioxidant, and anti-adhesive effects against bacteria, commonly used in the treatment of chronic obstructive pulmonary disease (COPD). In August 2022, another post-hoc analysis of the RESTORE study was published, evaluating the impact of its addition to COPD maintenance treatment on the incidence and severity of exacerbations and quality of life in patients with GOLD2 and GOLD3 grade bronchial obstruction.
News How to Improve Diabetic Adherence?
The dream of every doctor is a conscientious patient who follows the prescribed treatment and reports any potential problems in a timely manner. But where can such a patient be found?
News In decisions about therapeutic strategy in multiple myeloma, patient preferences and concerns also play a crucial role
The perspective on the preferences of patients with multiple myeloma (MM) is very necessary at a time of rapid development of new treatment options. Patient priorities and their perception of treatment can, alongside the assessment of the efficacy or toxicity of a modality, also influence decisions about the therapeutic strategy.
News Does Intense Monitoring After Colorectal Cancer Resection Bring Benefits?
Is it necessary to intensely monitor patients with colorectal cancer after curative resection? Not always, as shown by the results of the PRODIGE 13 study presented at the virtual ESMO 2020 conference.
News Efficacy and Safety of High Doses of Enoxaparin in Preventing Thromboembolic Disease in Morbidly Obese Patients
Thromboembolic disease is a significant cause of morbidity and mortality in hospitalized patients, with morbid obesity being a notable risk factor for thromboembolism. Various thromboprophylaxis strategies have been studied in morbidly obese patients; a recently published study compared the efficacy and safety of high doses of enoxaparin and unfractionated heparin.
News How do body weight and metabolic parameters change in patients first hospitalized for psychosis?
The most common cause of death in patients with schizophrenia is cardiovascular disease, which is closely related to obesity or metabolic syndrome. The study presented below examined changes in body weight and metabolic parameters during the first hospitalization of these patients.
News Safety of Dabigatran According to a Meta-Analysis of 7 Randomized Controlled Trials
Dabigatran is a direct thrombin inhibitor from the group of direct oral anticoagulants (DOACs), developed as an alternative to vitamin K antagonists. The aim of the recently published meta-analysis was to compare the risk of bleeding, fatal adverse events, and mortality in patients treated with dabigatran and conventional therapy.